ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

0SAN Sandoz Group Ag

0,00
0,00 (0,00%)
Nom Action Symbole Action Marché Type
Sandoz Group Ag 0SAN London Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,00 0,00% -
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
22/5/202407:00UKREGSandoz receives European Commission approval for Wyost® and..
07/5/202407:00UKREGSandoz reports first quarter 2024 sales
30/4/202412:25UKREGShareholders approve all resolutions proposed by Board of..
30/4/202407:00UKREGSandoz reaches agreement with Amgen resolving all patent..
22/4/202407:00UKREGSandoz confirms European Commission approval of Pyzchiva®..
21/3/202414:00UKREGSandoz opens new antibiotic production facility in Austria,..
13/3/202407:00UKREGSandoz reports fourth quarter 2023 sales and full-year 2023..
05/3/202419:24UKREGSandoz receives FDA approval for first and only denosumab..
05/3/202407:00UKREGSandoz announces nominations to the Board of Directors and..
04/3/202407:00UKREGSandoz acquires CIMERLI® business from Coherus, further..
29/2/202407:00UKREGSandoz US subsidiaries resolve generic drug antitrust class..
01/2/202407:15UKREGSandoz announces changes in the Board of Directors
31/1/202407:00UKREGSandoz launches first and only biosimilar for multiple..
22/1/202407:00GLOBESandoz announces agreement to acquire CIMERLI® business from..
21/11/202307:00GLOBESandoz launches Hyrimoz® (adalimumab) high-concentration..
10/11/202314:02GLOBESandoz inaugurates new antibiotic production plant in..
08/11/202318:46GLOBESandoz successfully issues EUR 2.0 billion inaugural..
26/10/202317:45GLOBESandoz successfully issues CHF 750 million in inaugural..
24/10/202307:15GLOBESandoz reports year-to-date sales for the first nine months..

Dernières Valeurs Consultées